147 related articles for article (PubMed ID: 31113837)
1. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs.
Weir SJ; Wood R; Schorno K; Brinker AE; Ramamoorthy P; Heppert K; Rajewski L; Tanol M; Ham T; McKenna MJ; McCulloch W; Dalton M; Reed GA; Jensen RA; Baltezor MJ; Anant S; Taylor JA
J Pharmacol Exp Ther; 2019 Aug; 370(2):148-159. PubMed ID: 31113837
[TBL] [Abstract][Full Text] [Related]
2. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.
Weir SJ; Dandawate P; Standing D; Bhattacharyya S; Ramamoorthy P; Rangarajan P; Wood R; Brinker AE; Woolbright BL; Tanol M; Ham T; McCulloch W; Dalton M; Reed GA; Baltezor MJ; Jensen RA; Taylor JA; Anant S
Cell Death Dis; 2021 May; 12(6):562. PubMed ID: 34059639
[TBL] [Abstract][Full Text] [Related]
3. Reposition of the Fungicide Ciclopirox for Cancer Treatment.
Huang Z; Huang S
Recent Pat Anticancer Drug Discov; 2021; 16(2):122-135. PubMed ID: 33573561
[TBL] [Abstract][Full Text] [Related]
4. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
Minden MD; Hogge DE; Weir SJ; Kasper J; Webster DA; Patton L; Jitkova Y; Hurren R; Gronda M; Goard CA; Rajewski LG; Haslam JL; Heppert KE; Schorno K; Chang H; Brandwein JM; Gupta V; Schuh AC; Trudel S; Yee KW; Reed GA; Schimmer AD
Am J Hematol; 2014 Apr; 89(4):363-8. PubMed ID: 24273151
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Naesens L; Balzarini J; Bischofberger N; De Clercq E
Antimicrob Agents Chemother; 1996 Jan; 40(1):22-8. PubMed ID: 8787873
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
Shaw JP; Sueoko CM; Oliyai R; Lee WA; Arimilli MN; Kim CU; Cundy KC
Pharm Res; 1997 Dec; 14(12):1824-9. PubMed ID: 9453075
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
8. Molecular-Level Control of Ciclopirox Olamine Release from Poly(ethylene oxide)-Based Mucoadhesive Buccal Films: Exploration of Structure-Property Relationships with Solid-State NMR.
Urbanova M; Gajdosova M; Steinhart M; Vetchy D; Brus J
Mol Pharm; 2016 May; 13(5):1551-63. PubMed ID: 27019088
[TBL] [Abstract][Full Text] [Related]
9. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.
Al-Zubaydi F; Gao D; Kakkar D; Li S; Holloway J; Szekely Z; Chan N; Kumar S; Sabaawy HE; Love S; Sinko PJ
Drug Deliv Transl Res; 2022 Jan; 12(1):240-256. PubMed ID: 33590464
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.
Mihailidou C; Papakotoulas P; Papavassiliou AG; Karamouzis MV
Oncotarget; 2018 Feb; 9(12):10360-10374. PubMed ID: 29535812
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats.
Bangphumi K; Kittiviriyakul C; Towiwat P; Rojsitthisak P; Khemawoot P
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):777-785. PubMed ID: 26563392
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats.
Shaw JP; Louie MS; Krishnamurthy VV; Arimilli MN; Jones RJ; Bidgood AM; Lee WA; Cundy KC
Drug Metab Dispos; 1997 Mar; 25(3):362-6. PubMed ID: 9172955
[TBL] [Abstract][Full Text] [Related]
13. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.
Eberhard Y; McDermott SP; Wang X; Gronda M; Venugopal A; Wood TE; Hurren R; Datti A; Batey RA; Wrana J; Antholine WE; Dick JE; Schimmer AD
Blood; 2009 Oct; 114(14):3064-73. PubMed ID: 19589922
[TBL] [Abstract][Full Text] [Related]
14. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy.
Al-Zubaydi F; Gao D; Kakkar D; Li S; Adler D; Holloway J; Szekely Z; Gu Z; Chan N; Kumar S; Love S; Sinko PJ
J Control Release; 2020 Jul; 323():71-82. PubMed ID: 32302762
[TBL] [Abstract][Full Text] [Related]
15. Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits.
Gajdošová M; Vetchý D; Muselík J; Gajdziok J; Juřica J; Vetchá M; Hauptman K; Jekl V
Int J Pharm; 2021 Jan; 592():120086. PubMed ID: 33188896
[TBL] [Abstract][Full Text] [Related]
16. In vitro model of infected stratum corneum for the efficacy evaluation of poloxamer 407-based formulations of ciclopirox olamine against Trichophyton rubrum as well as differential scanning calorimetry and stability studies.
Täuber A; Müller-Goymann CC
Int J Pharm; 2015 Oct; 494(1):304-11. PubMed ID: 26276254
[TBL] [Abstract][Full Text] [Related]
17. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy.
Weir SJ; Patton L; Castle K; Rajewski L; Kasper J; Schimmer AD
J Clin Pharm Ther; 2011 Apr; 36(2):128-34. PubMed ID: 21366640
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration].
Kellner HM; Arnold C; Christ OE; Eckert HG; Herok J; Hornke I; Rupp W
Arzneimittelforschung; 1981; 31(8A):1337-53. PubMed ID: 7197541
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
[TBL] [Abstract][Full Text] [Related]
20. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
